Condition: Carcinoma, Hepatocellular · Neoplasms, Glandular and Epithelial · Adenocarcinoma · Sponsor: Shanghai Zhongshan Hospital
This study is a prospective, single-arm, single-center trial evaluating the efficacy of TACE combined with multimodal ablation, Tislelizumab, and lenvatinib in the treatment of unresectable primary liver cancer.
This description comes directly from the study's public registry record.
zhiping Yan, M.D · +86 13122806500 · yan.zhiping@zs-hospital.sh.cn
Always discuss trial participation with your own doctor first.
| Zhongshan Hospital, Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06794073